Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.

Melissa CambronJop MostertMarie D'HoogheGuy NagelsBarbara WillekensJan DebruyneLuc AlgoedWim VerhagenRaymond HuppertsDorothea HeersemaJacques De Keysernull null

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2019)

The trial failed to demonstrate a neuroprotective effect of fluoxetine in patients with progressive MS.

Keyphrases

multiple sclerosis
phase iii
study protocol
phase ii
white matter
clinical trial
randomized controlled trial
ms ms
cerebral ischemia